A detailed history of B Group, Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, B Group, Inc. holds 1,255,556 shares of TSHA stock, worth $3.38 Million. This represents 1.5% of its overall portfolio holdings.

Number of Shares
1,255,556
Previous 965,556 30.03%
Holding current value
$3.38 Million
Previous $1.67 Billion 4.48%
% of portfolio
1.5%
Previous 1.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$1.39 - $2.05 $403,100 - $594,500
290,000 Added 30.03%
1,255,556 $1.75 Billion
Q4 2024

Feb 14, 2025

BUY
$1.27 - $3.24 $1.23 Million - $3.13 Million
965,556 New
965,556 $1.67 Billion

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $130M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track B Group, Inc. Portfolio

Follow B Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of B Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on B Group, Inc. with notifications on news.